Abstract 42P
Background
The study investigates the potential of OZ-001, a novel 3,4-dihydroquinazoline derivative containing a ureido group, against diverse cancers. Conventional chemotherapy has limited impact on triple-negative breast cancer (TNBC), and targeted TNBC therapies are lacking. OZ-001 is expected to target both signal transducer and activator of transcription 3 (STAT3) inhibition and T-type calcium channel blocking simultaneously.
Methods
The efficacy and potency of OZ-001 were assessed using MDA-MB-231 cells both in vitro and in vivo. Cell-based assays compassing cell viability, apoptosis, protein expression, cell cycle analysis, fluorescence polarization assay (FP), and intracellular calcium levels were conducted. An in vivo xenograft model using MB-231 cells gauged impact of OZ-001 via oral administration (ranging from 15 to 60mg/kg). Preliminary toxicity evaluation of OZ-001 was conducted using an in vivo model with RD rats.
Results
In vitro, OZ-001 displayed substantial does-dependent inhibition of cell viability inducing a remarkable 10-fold increase in apoptotic genes Bax and caspase-3 compared to the control. As a STAT3 inhibitor, OZ-001 effectively disrupted STAT3-STAT3 interactions in the FP assay, and it reduce STAT3 phosphorylation by 90%. As a T-type calcium channel blocker, OZ-001 exhibited the capability to reduce intracellular calcium levels by 50%, resulting in a notable 90% reduction in calcium signaling. In vivo, OZ-001 led to a 50% reduction in tumor size at a dose of 15mg/kg, and an impressive 95% at 60mg/kg (P.O.), compared to the vehicle-treated group, while a 70% reduction in tumor size at a dose of 10 mg/kg (IP) of Paclitaxel was observed. In a single oral dose toxicity evaluation using SD rats, no specific clinical sign or distinctive necropsy findings were observed, even at a dose of 2,000 mg/kg of OZ-001. This indicates its favorable safety profile.
Conclusions
OZ-001 emerges as a promising therapeutic candidate for TNBC, demonstrating exceptional efficacy as an orally active single agent in reducing tumor growth. The preclinical results present an encouraging avenue for further exploration and development of OZ-001 as a viable alternative for addressing TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ONCOZEN Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract